Evidence map›Paper›PMID 40033395›Full record

ArticleActa neuropathologica communications2025

Anlotinib may have a therapeutic effect on papillary craniopharyngiomas without the BRAFv600e mutation.

Yilamujiang Ainiwan, Haomin Li, Yongjia Zheng, Songtao Wei, Junxiang Peng, Jing Nie, Chaofu Mao, Kunxiang Chen, Siyuan Chen, Ningyuan Liu and 11 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Yilamujiang Ainiwan *Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Haomin Li *Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yongjia Zheng *First Clinical Medical College, Southern Medical University, Guangzhou, China.
Songtao Wei *Department of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Junxiang PengDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jing NieDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Chaofu MaoDepartment of Neurosurgery, Jinling Hospital, Xuanwu, China.
Kunxiang ChenDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Siyuan ChenDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ningyuan LiuDepartment of Neurology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Can LiCentral Laboratory, Southern Medical University, Guangzhou, Guangdong, China.
Yan ChenDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Shanqiang QuDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Yunji WangDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Mingfeng ZhouDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jian MaoDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Fen MeiDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Jingting ChenGuangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, Department of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Qiancheng SongDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China. songqc@smu.edu.cn.
Songtao QiDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China. qisongtaosjwk@163.com.
Jun PanDepartment of Neurosurgery, Nanfang Hospital, Southern Medical University, Guangzhou, China. 1448875873@qq.com.

Funding

National Natural Science Foundation of China: A study on the Mechanism of which beta-amyloid regulates the development of adamantinomatous craniopharyngioma by inducing senescence 32400973National Natural Science Foundation of China: Over-activation of cholesterol metabolism via AMPK-SREBP2 pathway in adamantinomatous craniopharyngioma induces microglial inflammatory response 81972352Natural Science Foundation of Guangdong Province,China 2024A1515010060
6 · The paper itself

Abstract

backgroundAlthough successful treatment of papillary craniopharyngiomas (PCPs) with BRAFv600e inhibitors has been reported in clinical trials, studies have shown that approximately 10% of PCPs lack the BRAFv600e mutation and that BRAFv600e inhibitors may not be significantly effective against these tumors. However, no studies have focused specifically on BRAFv600e

methodsSpatial transcriptome sequencing was performed on calcified PCP tissue to identify novel subtypes of PCP cells. The findings were validated via pathological methods in 51 PCP samples. Primary PCP cells from BRAFv600e

resultsMost of calcified PCPs were negative for the BRAFv600e mutation, and findings from the mouse model confirmed that vemurafenib may not have a significant therapeutic effect on BRAFv600e

conclusionBRAFv600e

Indexed as

Antineoplastic AgentsCraniopharyngiomaIndolesPituitary NeoplasmsProto-Oncogene Proteins B-rafQuinolinesAdultAnimalsFemaleHumansMaleMiceMice, NudeMiddle AgedMutationVemurafenibanlotinibAntineoplastic AgentsBRAF protein, humanIndolesProto-Oncogene Proteins B-rafQuinolinesVemurafenibAnlotinibBRAFv600e mutationCalcificationPapillary craniopharyngiomaVemurafenib

Identifiers

PMID40033395
PMCPMC11874662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.